Skip to main content Skip to section navigation Skip to footer
Bioscience Obesity
Our Company Pipeline Media & Investors Contact
Skye Bioscience, Inc. IR Overview
  • Investors
  • News
  • Company Info
    • Highlights
    • Corporate Presentation
    • IR Calendar/Webcasts
    • Executive Team
    • Email Alerts
    • Contacts
    • FAQ
  • Spotlight
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Analyst Coverage
    • Quote and Chart
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
  • Back to CorporateSite.com

News Releases

Investors

Investors

  • Overview
  • News
  • Company Info
    • Highlights
    • Corporate Presentation
    • IR Calendar/Webcasts
    • Executive Team
    • Email Alerts
    • Contacts
    • FAQ
  • Spotlight
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Analyst Coverage
    • Quote and Chart
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
Jun 2, 2020 8:30 am EDT
Emerald Bioscience Announces Awarding of Patent for Cannabidiol-Valine-Hemisuccinate in Japan

Apr 8, 2020 8:30 am EDT
Emerald Bioscience Joins Alliance for Biosecurity

Mar 9, 2020 8:30 am EDT
Emerald Bioscience Announces Notice of Allowance from United States Patent Office for Proprietary Analog of Cannabidiol

Jan 30, 2020 8:30 am EST
Emerald Bioscience to Present at the 9th Annual Glaucoma 360 New Horizons Forum and BIO CEO & Investor Forum

Jan 13, 2020 8:30 am EST
Emerald Bioscience Provides Update on Recent Progress and Expected 2020 Milestones

Jan 9, 2020 8:30 am EST
Emerald Bioscience to Present at Biotech Showcase 2020

Dec 23, 2019 8:30 am EST
Emerald Bioscience Announces Financing Update and Board Re-organization

Dec 10, 2019 8:30 am EST
Emerald Bioscience Inc. Announces Cannabidiol-Valine-Hemisuccinate Possesses Enhanced Anti-Seizure Activity when Compared with Cannabidiol (CBD) in the StemoniX Human Neural Tissue Platform

Dec 9, 2019 8:30 am EST
Emerald Bioscience Reports its Proprietary Analog of Cannabidiol, Cannabidiol-Valine-Hemisuccinate (CBDVHS), Exhibits Greater Potency and Antifibrotic Activity than Cannabidiol (CBD) in Biomarker Studies in Human Ocular Donor Tissues

Nov 21, 2019 9:12 am EST
Emerald Bioscience Announces $2.0 Million Registered Direct Offering

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • …
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • account_treeSitemap
11250 El Camino Real, Suite 100
San Diego, CA 92130
info@skyebioscience.com
Company
Our Company Careers Investors Contact
Product
Obesity
Media
News
© 2025 Skye Bioscience.
All Rights Reserved.
Terms of use Privacy Policy
Facebook Twitter LinkedIn